Clinical value of serum BMP-4, BMP-2, GDF-15, MMP-9, GP39 levels in pregnant women with obesity and the related comorbidities diabetes mellitus and gestational hypertension
Tarih
2023/2Yazar
YURTCU, NazanYarsilikal Guleroglu, Filiz
Selvi, Esra
uran Bakirci, Isil
Bafaloı, Olgu
Argun Atalmis, Hatice
Çetin, Ali
Üst veri
Tüm öğe kaydını gösterÖzet
Abstract
Aims We evaluated the clinical value of selected serum biomarkers BMP-4, BMP-2, GDF-15, MMP-9, and GP39 in pregnant women with obesity and the comorbidities diabetes mellitus (DM) and gestational hypertension (GHT).
Methods This observational study had groups of controls, including healthy pregnant women; women with only obesity, including pregnant women with BMI≥30 kg/m2; women with gestational DM (GDM) with obesity, including pregnant women with GDM and obesity; women with pregestational DM (PGDM) with obesity, including pregnant women with PGDM and obesity; and women with GHT with obesity, including pregnant women with GHT and obesity. We measured serum levels of selected biomarkers by ELISA.
ResultsObesity increased serum levels of all the biomarkers; GDM developed in obese women caused a more pronounced increase in the serum levels of BMP-4 and BMP-2, and GHT developed in obese women caused a more pronounced increase in the serum levels of GDF-15. In the women with GDM-, PGDM-, and GHT-complicated obesity, serum levels of MMP-9 and GP39 did not change meaningfully.
Conclusions Obesity and its comorbidities DM and GHT lead to meaningful changes in the studied serum biomarkers. Since obesity has a causal effect on developing numerous conditions, reliable clinical biomarkers are needed to improve the early prediction and diagnosis of high-risk conditions during pregnancy.
Kaynak
Zeitschrift für Geburtshilfe und NeonatologieCilt
227Sayı
01Bağlantı
https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1937-1155https://hdl.handle.net/20.500.12418/14925